Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIconic Labs Regulatory News (ICON)

Share Price Information for Iconic Labs (ICON)

Share Price is delayed by 15 minutes
Get Live Data
1.70    0.10 (6.25%)
Bid:
1.55
Ask:
1.85
Spread: 0.30 (19.355%)
Market Cap: £264.88k
ICON Live PriceLast checked at - London Stock Exchange

Intraday Iconic Labs Share Chart

Wideacademy Restructuring

30 Oct 2018 07:00

RNS Number : 5970F
WideCells Group PLC
30 October 2018
Ā 

30 October 2018

WideCells Group PLC ('WideCells Group' or 'the Group')

Ā 

Board Restructuring and Cost Cutting

Ā 

WideCells Group PLC, the healthcare services group focused on providing stem cell services and insurance for stem cell treatment, has undertaken further corporate restructuring and cost cutting measures to rationalise its Board and to refocus on its core operational divisions.

Ā 

As part of this restructuring, Alan Greenberg has resigned from his positions as a Director of the Board and Chief Business Development Officer and Senior Vice President of Wideacademy.

Ā 

In addition, the Company has closed Wideacademy's London office and has brought the division into the Manchester head office, thereby making annualised savings of approximately £400,000 pa.

Ā 

Wideacademy will continue to use its current collaborations with the education and medical sectors, and will harness Professor Peter Holland's knowledge in stem cell education and training to bolster the Group's stem cell storage and insurance sales.

Ā 

The Group's CEO, João Andrade, said, "I'd like to thank Alan Greenberg for his dedication to WideCells and I wish him all the best for the future. The streamlined Board and Wideacademy is now fully focused on increasing sales at our two core divisions - CellPlan, the world's first stem cell healthcare insurance plan; and WideCells, focused on stem cell storage and, research, in order to generate value for our shareholders."

Ā 

**ENDS**

Ā 

For further information, please visit the Company's website www.widecellsgroup.com, follow us on Twitter @WideCells_Group or contact:

Ā 

WideCells Group

CEO - João Andrade

Tel: +44 (0)161 920 7953

Shard Capital Partners LLP

Broker - Damon Heath & Erik Woolgar

Tel: +44 (0) 20 7186 9950

St Brides Partners Limited

PR - Isabel de Salis & Priit Piip

Tel: +44 (0) 20 7236 1177

Ā 

Notes to Editors

Ā 

WideCells Group PLC

WideCells Group PLC is building an integrated stem cell services company, focused on making stem cell treatments both accessible and affordable. This is delivered through three divisions:

Ā· CellPlan: the world's first stem cell healthcare insurance plan with financial cover for medical treatment, travel and accommodation expenses and concierge service to manage the treatment process.

Ā· WideCells: The Institute of Stem Cell Technology has been established and is based in the University of Manchester Innovation Centre to focus on stem cell research and regenerative medicine. WideCells also has international cryogenics divisions specialising in stem cell storage.

Ā· Wideacademy: developing an education and training division to promote awareness of the benefits of stem cell storage across the global general practice community.

Ā 

Stem Cell Fast Facts:

Ā· Cord blood (which is taken from the umbilical cord) provides the most effective source of stem cells for families, because it is simple, safe and painless to collect, relative to other sources of stem cells such as bone marrow - WideCells will focus on promoting the collection and storage of cord blood.

Ā· Since 2005, there has been a 300% increase in the number of illnesses that can be treated using stem cells.

Ā· 82 illnesses can currently be treated using stem cell procedures.

· Despite initial collection and storage often costing no more than a few £thousands, actual treatment can cost in the £hundreds of thousands - before the development of an insurance product such as CellPlan, the treatment remained largely available only to Higher Net Worth individuals.

Ā 

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 (MAR).

Ā 

Ā 

Ā 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
Ā 
END
Ā 
Ā 
BOADXBDGCGDBGIC
Date   Source Headline
30th Oct 20184:25 pmRNSNotice of AGM
30th Oct 20182:05 pmRNSSecond Price Monitoring Extn
30th Oct 20182:00 pmRNSPrice Monitoring Extension
30th Oct 20187:00 amRNSWideacademy Restructuring
29th Oct 20184:33 pmRNSHolding(s) in Company
23rd Oct 20188:27 amRNSConversion of Bond
22nd Oct 20183:27 pmRNSConversion of bonds
22nd Oct 20187:00 amRNSSmart Cells Deal
19th Oct 20189:20 amRNSHolding(s) in Company
18th Oct 201812:47 pmRNSBoard Restructuring
17th Oct 20184:48 pmRNSHolding(s) in Company
1st Oct 201811:00 amRNSPrice Monitoring Extension
28th Sep 20183:30 pmRNSHolding(s) in Company
27th Sep 20184:40 pmRNSSecond Price Monitoring Extn
27th Sep 20184:35 pmRNSPrice Monitoring Extension
27th Sep 201810:40 amRNSNotification of transactions of Directors
27th Sep 20187:10 amRNSInterim Results
27th Sep 20187:00 amRNSFinancing Agreement
30th Jul 20187:00 amRNSCellPlan Launch in Spain
9th Jul 20187:01 amRNSBoard Changes
9th Jul 20187:00 amRNSHolding(s) in Company
29th Jun 20183:00 pmRNSResult of AGM
28th Jun 201810:30 amRNSResult of General Meeting
15th Jun 20187:00 amRNSAlign Research Initiation of Coverage
12th Jun 20186:25 pmRNSProspectus and Notice of General Meeting
11th Jun 20189:00 amRNSLive Market Bookbuild Closes
11th Jun 20187:30 amRNSRestoration Widecells Group Plc
11th Jun 20187:00 amRNSUpdate Regarding Placing and Financial Position
6th Jun 20183:00 pmRNSNotice of AGM
5th Jun 20187:00 amRNSAudited Preliminary Results
21st May 20187:00 amRNSFinal Results Update
10th May 201810:30 amRNSPlacing to Raise £1.47m and Live Market Bookbuild
3rd May 20187:30 amRNSSuspension Widecells Group
1st May 20187:02 amRNSAnnual Accounts and Fundraising Update
26th Mar 20187:00 amRNSLandmark deal to launch CellPlan insurance in Asia
19th Mar 20187:00 amRNSGranted Innovate UK KTP for Stem Cell Research
27th Feb 20187:00 amRNSLicence Award from the Human Tissue Authority
19th Feb 20187:00 amRNSBoard Changes and Launch of Wideacademy Platform
21st Dec 20177:00 amRNSCorporate Update
2nd Nov 20177:00 amRNSRevenue generation with White Apex agreement
12th Oct 20177:00 amRNSCellPlan expansion, e-commerce platform launch UK
11th Oct 20177:00 amRNSPartner Secured to Expand into MENA & Asia-Pacific
29th Sep 20177:00 amRNSInterim Results
25th Sep 20177:00 amRNSWideacademy Update, Presenting at Investor Event
15th Aug 20177:00 amRNSRaises £750,000 to support Company's divisions
31st Jul 20177:00 amRNSResearch Licence Granted from HTA
24th Jul 20177:00 amRNSNew product to target the dental market
21st Jul 20177:00 amRNSCellPlan launches E-Commerce Platform in the UK
12th Jul 20177:00 amRNSCorporate Charity Commitment
4th Jul 20177:00 amRNSAgreement to Roll Out CellPlan in Brazil

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.